| 2 | Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons. (Schwab AJ, Sison SL, Meade MR, Broniowska KA, Corbett JA, Ebert AD) Stem Cell Reports 2017 Dec 12;9(6):1839-1852 66 Citations |
| 1 | Transcriptome-wide co-expression analysis identifies LRRC2 as a novel mediator of mitochondrial and cardiac function. (McDermott-Roe C, Leleu M, Rowe GC, Palygin O, Bukowy JD, Kuo J, Rech M, Hermans-Beijnsberger S, Schaefer S, Adami E, Creemers EE, Heinig M, Schroen B, Arany Z, Petretto E, Geurts AM) PLoS One 2017;12(2):e0170458 8 Citations |
| 1 | Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation. (Schwab AJ, Ebert AD) Stem Cell Reports 2015 Dec 08;5(6):1039-1052 71 Citations |
| 1 | Alterations in late endocytic trafficking related to the pathobiology of LRRK2-linked Parkinson's disease. (Rivero-Ríos P, Gómez-Suaga P, Fernández B, Madero-Pérez J, Schwab AJ, Ebert AD, Hilfiker S) Biochem Soc Trans 2015 Jun;43(3):390-5 26 Citations |
| 1 | Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition. (Hockey LN, Kilpatrick BS, Eden ER, Lin-Moshier Y, Brailoiu GC, Brailoiu E, Futter CE, Schapira AH, Marchant JS, Patel S) J Cell Sci 2015 Jan 15;128(2):232-8 141 Citations |
| 3 | A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease. (Dranka BP, Gifford A, McAllister D, Zielonka J, Joseph J, O'Hara CL, Stucky CL, Kanthasamy AG, Kalyanaraman B) Neurosci Lett 2014 Nov 07;583:159-64 40 Citations |
| 2 | Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse. (Dranka BP, Gifford A, Ghosh A, Zielonka J, Joseph J, Kanthasamy AG, Kalyanaraman B) Neurosci Lett 2013 Aug 09;549:57-62 31 Citations |
